1. Home
  2. BMRA vs PULM Comparison

BMRA vs PULM Comparison

Compare BMRA & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomerica Inc.

BMRA

Biomerica Inc.

HOLD

Current Price

$2.51

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Logo Pulmatrix Inc.

PULM

Pulmatrix Inc.

N/A

Current Price

$1.38

Market Cap

5.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BMRA
PULM
Founded
1971
2003
Country
United States
United States
Employees
50
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
5.7M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
BMRA
PULM
Price
$2.51
$1.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
187.3K
27.7K
Earning Date
04-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
39.81
46.18
EPS
N/A
N/A
Revenue
$4,453,000.00
$7,910,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5069.93
52 Week Low
$1.45
$1.16
52 Week High
$3.21
$5.50

Technical Indicators

Market Signals
Indicator
BMRA
PULM
Relative Strength Index (RSI) 71.51 43.68
Support Level $2.28 $1.21
Resistance Level $2.49 $1.44
Average True Range (ATR) 0.17 0.08
MACD 0.01 0.00
Stochastic Oscillator 97.92 23.33

Price Performance

Historical Comparison
BMRA
PULM

About BMRA Biomerica Inc.

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Share on Social Networks: